Controlled penetration depth
Energy delivered toward a defined target depth rather than an uncontrolled thermal front.
Endoscopic LASER Ablation Platform
Depth-controlled ablation for GI – Starting with Barrett's esophagus.
VeriDepth LX delivers contactless, pattern-based LASER energy to a defined target depth — designed to clear disease in fewer sessions while sparing the deeper layers.
The VeriDepth Difference
01
Controlled depth
Energy regulated toward a defined target depth.
02
Deeper layers spared
Muscle layer preserved at the chronic timepoint in preclinical study.
03
One and done workflow
Circumferential balloon coverage with precise focal treatment as needed, in a single pass.
About Digma Medical
Transforming Gastroenterology Care
Digma Medical Ltd. is a medical technology company dedicated to transforming the treatment of gastroenterology pathologies, starting with Barrett's Esophagus (BE) — a pre-cancerous condition that may progress to esophageal adenocarcinoma, one of the most deadly forms of GI cancer.
We are developing VeriDepth, a minimally invasive therapy that provides contactless, depth-controlled ablation guided by imaging. VeriDepth is designed to treat the full circumference of the esophagus or isolated patches in a single, short procedure that is safe and efficient — targeting mucosal tissue while protecting deeper layers such as the muscularis.
Our product consists of the VeriDepth LX console and a single-use catheter compatible with the working channel of standard gastrointestinal endoscopes. The VeriDepth procedure is being developed for performance in a standard GI endoscopy suite without requiring additional imaging equipment.
The VeriDepth procedure is currently being evaluated in clinical studies.
To learn more about our clinical program, please contact us. Contact us →
~292K
U.S. endoscopic ablation procedures per year for Barrett's
3+
sessions typically needed to clear a single patient today
Up to 35%
recurrence drives repeat cycles and ongoing surveillance
125×
increased risk of esophageal adenocarcinoma with Barrett's
The Problem
The problem isn't ablation. It's repeat procedures.
Today's standard of care works, but uncontrolled ablation depth leaves disease behind — driving recurrence, repeat sessions, and ongoing treatment burden for patients and endoscopy suites alike. The modality is two decades old, and depth has never been the variable it controlled.
01
Repeat sessions
Multiple ablation sessions to clear one patient, each with its own sedation and suite time.
02
Recurrence
Residual disease below the treated plane returns, restarting the treatment cycle.
03
Capacity drain
More sedations, more endoscopy-suite time, more patient drop-off before eradication.
The Platform
VeriDepth LX: precise, depth-controlled LASER ablation
A LASER console with a family of single-use balloon catheters, delivered through the working channel of standard GI endoscopes — in a standard endoscopy suite, with no additional imaging equipment.
One Platform
Console + catheter family
The console — placed capital equipment
Single-use catheters — multiple balloon sizes
Deeper layers spared
Designed to spare the layers whose injury drives stricture risk.
Pattern-based 3D maps
Customized ablation patterns for circumferential segments or isolated focal patches.
Non-contact delivery
Effective ablation without full tissue contact; a balloon centers the LASER for stable delivery.
Short procedure, high throughput
Multi-zone treatment in one session, with the potential to avoid general anesthesia.
Standard GI suite
Through-the-scope catheter, familiar endoscopic workflow, no fluoroscopy required.
Map & Mark Before Ablate
A visible guide pointer targets. The therapeutic LASER treats.
Dual-wavelength design pairs a visible red guide pointer for targeting with a near-infrared therapeutic LASER for ablation — the physician confirms the treatment zone before energy is delivered.
For Physicians
Built around the endoscopy suite
Adoption is won on time, simplicity, and fewer patients coming back. VeriDepth is designed to fit the workflow a GI physician already runs.
Fewer repeat procedures
Controlled depth targets recurrence, so fewer call-backs per patient.
Faster, simpler sessions
Circumferential balloon coverage with focal treatment as needed, in the same workflow.
Short learning curve
Balloon-based, familiar endoscopic technique with minimal retraining.
Physician-experience benefits are anticipated design outcomes, subject to validation in clinical studies.
The Condition
Barrett's Esophagus
A pre-cancerous condition caused by chronic reflux that may progress to esophageal adenocarcinoma — one of the deadliest GI cancers. Ablation eliminates abnormal tissue and enables healthy regeneration, but high recurrence with current therapies often requires multiple sessions.
01 Caused by chronic GERD; often progresses silently and is diagnosed late.
02 Symptoms include heartburn, regurgitation, and difficulty swallowing.
03 More than 12 million people are affected in the U.S., with 200K+ new cases each year.
04 Rising demand for safer, more durable, minimally invasive treatment.
Program Status
Regulatory, quality, and IP foundations in place
510(k) tool-claim path
Positive FDA feedback on the regulatory route.
ISO 13485 quality system
Design and manufacturing controls in place.
13 patents, FTO clear
Protected position with freedom to operate.
Prior human safety
Platform safety demonstrated in prior human use across 31 patients.
Path to Clinical Proof
2026
First-in-human pilot and GLP animal studies
2027
CE and FDA 510(k) clearance, tool claim
2028
Barrett's clearance and soft launch at reference centers
2029+
Commercial scale-up and global expansion
Forward-looking development plan. Timelines are targets and subject to clinical, regulatory, and business outcomes.
Team
Operators who have built, cleared, and exited GI devices.
Shlomit Chappel-Ram, PhD, MBA
General Manager
Dr. Shlomit Chappel-Ram is an accomplished executive with over 20 years of leadership in the medical device and life sciences industries. At Digma Medical, she leads strategic operations, product development, and fundraising efforts for the company's endoscopic LASER therapy platform. Prior to Digma, she held senior roles at Nano Dimension, Edwards Lifesciences, and Medinol, driving innovation from early-stage development through commercialization. Dr. Chappel-Ram holds a PhD in Chemistry (Summa Cum Laude) and an MBA in Management.
Ilan Ben-Oren
Co-founder and CTO
Ilan brings more than 25 years of experience in R&D and management in the medical device industry. In addition to co-founding Digma, he served as founder and CTO of Eximo Medical (acquired by AngioDynamics), CTO of Exalenz Bioscience Ltd. (acquired by Meridian BioScience), and CTO at Oridion Medical (acquired by Covidien). Ilan is the author of more than 60 patents and patent applications in medical technologies and electro-optics. He holds a master's degree in applied physics and the science of materials, summa cum laude, from the Hebrew University of Jerusalem.
Dr. Irit Yaniv, MD
Co-Founder & Director
Dr. Irit Yaniv is the Founding Partner and CEO of Almeda Ventures and Managing Partner at Accelmed Ventures II, with over 25 years of experience in venture capital, pharmaceutical, and biotech industries. As a senior manager, skilled physician, and experienced board member, she combines leadership, decision-making, and business expertise. She holds an MD from Ben-Gurion University and an MBA from Tel Aviv University.
Christopher Rowland
Chairperson
Christopher Rowland is a veteran MedTech executive with 35+ years leading medical device companies from startup to exit, including 17 years in GI/endoscopy at Boston Scientific. A President & CEO for more than 15 years, he has led organizations acquired by Medtronic, Teleflex, and a Chinese strategic. He currently serves as Board Chairman of Endostart, EvoEndo, and Keyron Medical Technologies, and advises several early- and growth-stage ventures across endoscopy, urology, and minimally invasive surgery.
Dr. Charles Carignan, MD
Board Member
Dr. Charles Carignan is a physician-executive with deep experience across cardiovascular and gastrointestinal device development. He previously served as Chief Medical Officer of Boston Scientific, Executive Vice President and Chief Medical Officer of Novasys Medical, and has led multiple medical device companies as CEO, including Sonivie, Bionx, and founding president and CEO of NinePoint Medical.
Dr. Suzan Alpert, MD, PhD
Regulatory Consultant
Dr. Suzan Alpert brings deep regulatory expertise from senior roles overseeing medical device review and approval, including as Chief Regulatory Officer at Medtronic, VP of Regulation at C.R. Bard, and Director of the FDA's Office of Device Evaluation.
Clinical KOLs
Dr. Michael B. Wallace
Mayo Clinic
Dr. Seth A. Gross
NYU Langone
Prof. Ohad Etzion
Soroka — Trial design
Backed by
Digma Medical is a privately held company backed by leading venture capital firms.
Company Overview
Quality & Certification
Independently audited medical device quality management
Digma Medical Ltd. operates a quality management system certified to ISO 13485:2016 by the Standards Institution of Israel (SII), Quality & Certification Division.
Certification scope
Design, development, and manufacture of endoscopic gastrointestinal ablation devices for therapeutic applications in the digestive tract.
Standard ISO 13485:2016
Certification body Standards Institution of Israel (SII)
Certificate No. 114182
Valid until 18 August 2027
This certification applies to our quality management system and reflects independently audited processes. It does not indicate regulatory approval or commercial availability of any specific product.
Contact
Let's talk about the clinical program
For clinical program inquiries, partnerships, investor relations, or general information.
Email
info@digmamedical.com Phone
03-6734561